Evidence map›Paper›PMID 38862465›Full record

ArticleNature communications2024

Impact of keratocyte differentiation on corneal opacity resolution and visual function recovery in male rats.

Andri K Riau, Zhuojian Look, Gary H F Yam, Craig Boote, Qian Ma, Evelina J Y Han, Nur Zahirah Binte M Yusoff, Hon Shing Ong, Tze-Wei Goh, Nuur Shahinda Humaira Binte Halim and 1 more

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Long-Term Tolerability and Safety of AAV5-Id3 Gene Therapy to Eyes.Translational vision science & technology · 2026
    Article
  8. Article
  9. Article
  10. Biomedical Application of MSCs in Corneal Regeneration and Repair.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Andri K Riau *Tissue Engineering and Cell Therapy Group, Singapore Eye Research Institute, Singapore, 169856, Singapore.ORCID http://orcid.org/0000-0002-5105-0484
Zhuojian Look *Tissue Engineering and Cell Therapy Group, Singapore Eye Research Institute, Singapore, 169856, Singapore.ORCID http://orcid.org/0000-0002-7977-2446
Gary H F YamTissue Engineering and Cell Therapy Group, Singapore Eye Research Institute, Singapore, 169856, Singapore.
Craig BooteSchool of Optometry and Vision Sciences, Cardiff University, Cardiff, CF24 4HQ, UK.
Qian MaSchool of Optometry and Vision Sciences, Cardiff University, Cardiff, CF24 4HQ, UK.ORCID http://orcid.org/0000-0002-3473-1544
Evelina J Y HanTissue Engineering and Cell Therapy Group, Singapore Eye Research Institute, Singapore, 169856, Singapore.
Nur Zahirah Binte M YusoffTissue Engineering and Cell Therapy Group, Singapore Eye Research Institute, Singapore, 169856, Singapore.
Hon Shing OngTissue Engineering and Cell Therapy Group, Singapore Eye Research Institute, Singapore, 169856, Singapore.ORCID http://orcid.org/0000-0001-5475-8712
Tze-Wei GohTissue Engineering and Cell Therapy Group, Singapore Eye Research Institute, Singapore, 169856, Singapore.
Nuur Shahinda Humaira Binte HalimTissue Engineering and Cell Therapy Group, Singapore Eye Research Institute, Singapore, 169856, Singapore.
Jodhbir S MehtaTissue Engineering and Cell Therapy Group, Singapore Eye Research Institute, Singapore, 169856, Singapore. jodhbir.s.mehta@singhealth.com.sg.ORCID http://orcid.org/0000-0001-6362-4898

Funding

Virus Production and Manipulation of Protein/Gene Expression ModuleP30EY008098 · NEI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Ethan A Rossi · 1989 to 2026
$17.8M
MOH | National Medical Research Council (NMRC) MOH-000197-00NEI NIH HHS P30 EY008098
6 · The paper itself

Abstract

Intrastromal cell therapy utilizing quiescent corneal stromal keratocytes (qCSKs) from human donor corneas emerges as a promising treatment for corneal opacities, aiming to overcome limitations of traditional surgeries by reducing procedural complexity and donor dependency. This investigation demonstrates the therapeutic efficacy of qCSKs in a male rat model of corneal stromal opacity, underscoring the significance of cell-delivery quality and keratocyte differentiation in mediating corneal opacity resolution and visual function recovery. Quiescent CSKs-treated rats display improvements in escape latency and efficiency compared to wounded, non-treated rats in a Morris water maze, demonstrating improved visual acuity, while stromal fibroblasts-treated rats do not. Advanced imaging, including multiphoton microscopy, small-angle X-ray scattering, and transmission electron microscopy, revealed that qCSK therapy replicates the native cornea's collagen fibril morphometry, matrix order, and ultrastructural architecture. These findings, supported by the expression of keratan sulfate proteoglycans, validate qCSKs as a potential therapeutic solution for corneal opacities.

Indexed as

Cell DifferentiationCorneal KeratocytesCorneal OpacityAnimalsCorneaCorneal StromaDisease Models, AnimalHumansMaleRatsRats, Sprague-DawleyRecovery of FunctionVisual Acuity

Identifiers

PMID38862465
PMCPMC11166667

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.